Anatara Lifesciences Ltd (AU:ANR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Anatara Lifesciences is advancing its GaRP-IBS clinical trial, having reached the minimum participant requirement for Stage 2 and pausing recruitment from December 13, 2024. The trial aims to explore new treatments for Irritable Bowel Syndrome, with headline results expected in the first quarter of 2025. The company’s proactive recruitment strategy has successfully engaged participants across key sites.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue